'36% cheaper than the original to ease patient burden'
CMG Pharmaceutical, a subsidiary of Chabiotech, has launched Edoxin (edoxaban), an oral anticoagulant tablet.
Edoxin is the first generic of Lixiana, an oral anticoagulant marketed in South Korea by Daiichi Sankyo Korea, released following the expiration of the original drug's substance patent. The generic uses the same salt form and formulation as the original.
Edoxaban is an oral anticoagulant that selectively inhibits blood coagulation factor Xa. It is indicated for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for the treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism.
Edoxin has been confirmed bioequivalent to the original drug and uses a registered drug master file active pharmaceutical ingredient. CMG Pharmaceutical said the launch marks its entry into the oral anticoagulant market and that it plans to expand its cardiovascular product lineup.
The reimbursed price for both the 30 mg and 60 mg strengths is 914 won per tablet — 36 percent lower than the 1,422 won per tablet price of the original, which was reduced upon the generic's entry. Lixiana's domestic outpatient prescription sales in 2025 reached approximately 121.8 billion won ($91.3 million).
"We expect this to help reduce the medication cost burden for patients requiring continuous anticoagulation therapy and to broaden their treatment options," CMG Pharmaceutical said.
freiheit@heraldcorp.com
